Loading
Everything OnCo dates to 2004: 129 entries, 28 landmarks, 26 papers listed on people's pages, 23 papers and 19 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
129 dated entries in OnCo fall in 2004: 28 landmarks, 26 papers listed on people's pages, 23 papers, 19 approvals, 10 trials reported, 8 companies founded, 5 journals founded, 5 regulatory events, 3 technologies and 2 laws and regulations.
Of those, 1 to the day, 3 to the month and 125 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Elevated platelet counts in at-risk essential thrombocythaemia intolerant of or inadequately controlled by current therapy (Xagrid)
Myelodysplastic syndromes
First-line metastatic colorectal cancer with 5-FU chemotherapy
EGFR-expressing metastatic colorectal cancer; later restricted to RAS wild-type. Erbitux marketing authorisation issued 29 June 2004.
EGFR-expressing metastatic colorectal cancer (later restricted to RAS wild-type)
Hypercalcaemia in patients with parathyroid carcinoma; secondary hyperparathyroidism on dialysis; primary hyperparathyroidism when surgery is not possible
Hairy cell leukaemia (Litak, subcutaneous)
Relapsed or refractory ALL in patients aged 1 to 21 after at least two prior regimens (accelerated)
Metastatic CRPC (with prednisone)
Locally advanced/metastatic NSCLC after chemotherapy
Adjuvant stage III colon cancer (oxaliplatin, MOSAIC)
Metastatic breast cancer with paclitaxel
Rituximab-relapsed or refractory CD20-positive follicular lymphoma; first-line consolidation added 2008
Actinic keratosis; superficial basal cell carcinoma in immunocompetent adults
Thin non-hyperkeratotic actinic keratoses of the face and scalp, with red light photodynamic therapy
Advanced adrenocortical carcinoma
Adjuvant stage III colon cancer
Reduction of severe oral mucositis in haematological malignancies with myelotoxic therapy and autologous stem cell support
Unresectable pleural mesothelioma with cisplatin
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
First generics
Launched as a laboratory-developed test
First anti-angiogenic approval (AVF2107)
Initial approval in EGFR-expressing mCRC (BOND trial)
First hypomethylating agent approved (MDS)
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
European Union, regulation.
European Union, regulation.
The year reported on trial records, with the headline result the record gives.
Median overall survival 20.3 against 15.6 months, hazard ratio 0.66.
In advanced disease, chemotherapy gave a hazard ratio for death of 0.77 and a median gain of nine weeks; in the surgical and radical radiotherapy settings there was no survival ben...
10-year locoregional recurrence 10% (tamoxifen alone) vs 2% (tamoxifen plus radiotherapy); no survival difference.
5-year local recurrence 6% (preoperative) vs 13% (postoperative); overall survival unchanged.
Pain response to initial treatment 71 percent after a single 8 Gy fraction against 73 percent after 24 Gy in multiple fractions (p=0.84); retreatment raised the single-fraction fig...
Five-year survival 21 percent with adjuvant chemotherapy against 8 percent without (p 0.009); 10 percent with chemoradiotherapy against 20 percent without (p 0.05).
Five-year survival 44.5 against 40.4 percent (hazard ratio for death 0.86).
Three-year disease-free survival 78.2 against 72.9 percent (hazard ratio 0.77); six-year overall survival benefit in stage III only.
Median overall survival 17.5 against 15.6 months (hazard ratio for death 0.80, 95 percent confidence interval 0.67 to 0.97, p=0.02) and time to progression 6.3 against 3.2 months...
Median survival 18.9 months with three-weekly docetaxel against 16.5 months with mitoxantrone (hazard ratio for death 0.76, 95 percent confidence interval 0.62 to 0.94, p=0.009), w...
The publication year on key paper records.
Neoptolemos JP, Stocken DD, Friess H, et al. New England Journal of Medicine.
Lynch TJ, Bell DW, Sordella R, et al. New England Journal of Medicine.
Heinlein CA, Chang C. Endocrine reviews.
Cristofanilli M, Budd GT, Ellis MJ, et al. New England Journal of Medicine.
Dhebri AR, Connor S, Campbell F, Ghaneh P, Sutton R, Neoptolemos JP. Pancreatology.
Paez JG, Jänne PA, Lee JC, et al. Science.
Bernier J, Domenge C, Ozsahin M, et al. New England Journal of Medicine.
Doll R, Peto R, Boreham J, Sutherland I. BMJ.
Wistuba II, Gazdar AF. Nature Reviews Cancer.
Hurwitz H, Fehrenbacher L, Novotny W, et al. New England Journal of Medicine.
Hughes KS, Schnaper LA, Berry D, et al. New England Journal of Medicine.
Hassan R, Bera T, Pastan I. Clinical Cancer Research.
Chen CD, Welsbie DS, Tran C, et al. Nature Medicine.
Habr-Gama A, Perez RO, Nadalin W, et al. Annals of Surgery.
André T, Boni C, Mounedji-Boudiaf L, et al. New England Journal of Medicine.
Cooper JS, Pajak TF, Forastiere AA, et al. New England Journal of Medicine.
Sauer R, Becker H, Hohenberger W, et al. New England Journal of Medicine.
De Santis M, Becherer A, Bokemeyer C, et al. Journal of Clinical Oncology.
Singh SK, Hawkins C, Clarke ID, et al. Nature.
Petrylak DP, Tangen CM, Hussain MH, et al. New England Journal of Medicine.
Tannock IF, de Wit R, Berry WR, et al. New England Journal of Medicine.
Maffini MV, Soto AM, Calabro JM, et al. Journal of cell science.
Xia ZJ, Chang JH, Zhang L, et al. Ai Zheng (Chinese Journal of Cancer).
The history entries editors wrote on cancer records: the dated turning points of each disease.
Myelodysplastic syndromes / neoplasms (MDS). First drug approved for MDS (US); AZA-001 (2009) shows survival benefit in higher-risk disease.
Acute myeloid leukaemia. First hypomethylating agent; later the AML backbone for venetoclax and IDH/menin combinations.
Higher-risk myelodysplastic syndromes
Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms
Acute myeloid leukaemia in older or unfit patients
HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)
Colorectal cancer. First anti-angiogenic and first anti-EGFR antibodies; MOSAIC establishes adjuvant FOLFOX.
Rectal cancer
Parathyroid carcinoma. Including hypercalcaemia of parathyroid carcinoma (FDA).
Non-small-cell lung cancer. Lynch, Paez, and Pao identify activating EGFR mutations; the birth of lung cancer precision medicine.
Lung cancer (all types)
EGFR-mutated non-small-cell lung cancer
Pancreatic ductal adenocarcinoma. 289 patients; five-year survival 21 versus 8 percent with chemotherapy, 10 versus 20 percent with chemoradiotherapy.
Follicular lymphoma
Uveal melanoma
Rectal cancer
HER2-mutant non-small-cell lung cancer
Thymic carcinoma
High-risk early HR-positive breast cancer
Prostate cancer. A modest rise in androgen receptor expression, with no mutation, is shown to be necessary and sufficient for antiandrogen resistance and to turn antagonists into a...
HR-positive / HER2-negative breast cancer. Gene-expression recurrence score enters practice.
Mesothelioma
Mesothelioma
Brain metastases (secondary brain tumours)
Germ cell tumours of childhood and adolescence (extracranial and CNS). POG/CCG intergroup studies show surgery alone is safe for low-stage disease.
Metastatic castration-resistant prostate cancer
Prostate cancer. TAX 327 gave median survival of 18.9 months with three-weekly docetaxel against 16.5 with mitoxantrone, and improved pain and quality of life; SWOG 9916 reported 1...
Low-grade serous ovarian cancer
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Thousand Oaks, CA
Houston, TX
Uppsala
Menlo Park, CA
Zurich
Nerviano
Shanghai
Denver, CO
The founded year on journal records.
International Institute of Anticancer Research
Akademperiodyka (National Academy of Sciences of Ukraine)
Springer Nature
Wiley
Public Library of Science
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
European Journal of Nuclear Medicine and Molecular Imaging
Journal of Clinical Oncology
PNAS
Cancer
Cancer
Transplantation
Cancer Investigation
Critical Care Medicine
Mutat Res
NEJM
Nature
Exogenous Dermatology
Science
Cell Cycle
BMJ
Nucleic Acids Res
Journal of Pediatric Hematology/Oncology
The Annals of Thoracic Surgery
Vaccine
International Journal of Radiation Oncology, Biology, Physics
Journal of Clinical Oncology
Nature Reviews Immunology
American Journal of Hematology
Cancer Cell
Journal of Neurosurgery
Leukemia